Therapy Areas: Oncology
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
9 January 2026 - Acousia Therapeutics GmbH, a clinical-stage biotechnology company based in Germany, announced on Thursday that it has completed patient enrolment in its Phase 2 PROHEAR clinical study...
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
9 January 2026 - Clinical-stage life sciences company ZYUS Life Sciences Corporation (TSXV:ZYUS) on Thursday reported favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatmen...
DELFI Diagnostics names new chief financial officer
9 January 2026 - DELFI Diagnostics Inc, a developer of next-generation, blood-based tests to help detect cancer, announced on Thursday the appointment of Cindy Soriano as chief financial officer, effe...
Arbele's ARB1002 receives US FDA Orphan Drug Designation
8 January 2026 - Arbele, a Hong Kong-based biotechnology company focused on developing innovative targeted cancer therapies, announced on Wednesday that it has received Orphan Drug Designation (ODD) f...
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
7 January 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) on Wednesday reported positive phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense olig...
Day One completes Mersana acquisition to add rare cancer antibody drug conjugate
6 January 2026 - US-based biopharmaceutical company Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) announced on Tuesday that it has completed its acquisition of Mersana Therapeutics, Inc. (NASDAQ: MR...